SC high court cuts J&J's Risperdal marketing penalty back again, to $124M

South Carolina's Supreme Court further cut the penalty against Johnson & Johnson ($JNJ) stemming from a Risperdal deceptive-marketing lawsuit. Originally ordered to pay $327 million for violations of the state's Unfair Trade Practices Act, J&J's Janssen Pharmaceutica unit now faces a $124 million judgment. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.